The cardiovascular action of hexarelin
10.11909/j.issn.1671-5411.2014.03.007
- Author:
Wyuanjie MAO
;
Takeshi TOKUDOME
;
Ichiro KISHIMOTO
- Publication Type:Journal Article
- Keywords:
Hexarelin;
Cardiovascular disease;
Growth hormone secretagogue receptor;
CD36
- From:
Journal of Geriatric Cardiology
2014;(3):253-258
- CountryChina
- Language:Chinese
-
Abstract:
Hexarelin, a synthetic growth hormone-releasing peptide, can bind to and activate the growth hormone secretagogue receptor (GHSR) in the brain similar to its natural analog ghrelin. However, the peripheral distribution of GHSR in the heart and blood vessels suggests that hexarelin might have direct cardiovascular actions beyond growth hormone release and neuroendocrine effects. Furthermore, the non-GHSR CD36 had been demonstrated to be a specific cardiac receptor for hexarelin and to mediate its cardioprotective effects. When compared with ghrelin, hexarelin is chemically more stable and functionally more potent. Therefore, it may be a promising therapeutic agent for some car-diovascular conditions. In this concise review, we discuss the current evidence for the cardiovascular action of hexarelin.
